Novavax, swamped with FDA's manufacturing 'questions,' hopes for U.S. coronavirus shot trial by the end of the year

With two players in the race for a COVID-19 vaccine nearing the finish line on world-first regulatory approvals, Maryland biotech Novavax continues to lag behind in getting its candidate into a late-stage trial in the U.S. Now, that trial has been pushed back further as the FDA targets its manufacturing plans.